Artiva Biotherapeutics CEO reports tax withholding and 6,375-share sale

Rhea-AI Filing Summary

Artiva Biotherapeutics (ARTV) President and CEO, who is also a director, reported routine equity transactions. On 11/15/2025, 6,347 shares of common stock were withheld by the company at $3.25 per share to cover income taxes from vesting restricted stock units. On 11/17/2025, the insider sold 6,375 shares of common stock at a weighted average price of $3.376 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on July 23, 2024. Following these transactions, the insider directly beneficially owned 343,999 shares of Artiva common stock.

Insider Trade Summary

Net Seller: 12,722 shares

Net Sell 2 txns

Insider Aslan Fred

Role President and CEO

Sold 6,375 shs ($22K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,375	$3.376	$22K
Exercise Price or Tax Liability	Common Stock	6,347	$3.25	$21K

Holdings After Transaction: Common Stock — 343,999 shares (Direct)

Footnotes (3)

1. F1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
2. F2. The reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024.
3. F3. The weighted average sale price for the transaction reported was $3.376, and the range of prices were between $3.19 and $3.53. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/17/2025 - 08:37 PM Learn about SEC filing dates

FAQ

What insider activity did Artiva Biotherapeutics (ARTV) report on this Form 4?

The Form 4 reports that Artiva Biotherapeutics' President and CEO, who is also a director, had 6,347 shares withheld for taxes related to restricted stock unit vesting and sold 6,375 shares of common stock in a separate transaction.

How many Artiva (ARTV) shares did the CEO sell and at what price?

On 11/17/2025, the CEO sold 6,375 shares of Artiva common stock at a weighted average price of $3.376 per share, with individual sale prices ranging from $3.19 to $3.53.

Were any Artiva (ARTV) shares withheld for taxes in this Form 4?

Yes. On 11/15/2025, 6,347 shares of Artiva common stock were withheld by the issuer at a price of $3.25 per share to satisfy income tax obligations from the vesting of restricted stock unit awards.

Is the Artiva (ARTV) CEO sale part of a Rule 10b5-1 trading plan?

Yes. The sale of 6,375 shares on 11/17/2025 was executed under a Rule 10b5-1 plan that the reporting person adopted on July 23, 2024.

How many Artiva Biotherapeutics (ARTV) shares does the CEO own after these transactions?

After the reported tax withholding and sale transactions, the CEO directly beneficially owned 343,999 shares of Artiva Biotherapeutics common stock.

Does the Form 4 give details on the price range for the Artiva (ARTV) share sale?

Yes. It states that the weighted average sale price was $3.376 per share and that individual sale prices ranged between $3.19 and $3.53. Detailed price-by-lot information is available upon request to the company, the SEC staff, or any security holder.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aslan Fred

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/15/2025		F		6,347(1)	D	$3.25	350,374	D
Common Stock	11/17/2025		S(2)		6,375	D	$3.376(3)	343,999	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

2. The reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024.

3. The weighted average sale price for the transaction reported was $3.376, and the range of prices were between $3.19 and $3.53. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Neha Krishnamohan, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.